Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Perspective Therapeutics (CATX), Baxter International (BAX) and Arvinas Holding Company (ARVN)

Tipranks - Tipranks - Wed Mar 18, 6:46AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Perspective Therapeutics (CATX – Research Report), Baxter International (BAX – Research Report) and Arvinas Holding Company (ARVN – Research Report).

Claim 70% Off TipRanks Premium

Perspective Therapeutics (CATX)

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on Perspective Therapeutics. The company’s shares closed last Monday at $5.22.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 17.8% and a 46.4% success rate. Renza covers the Healthcare sector, focusing on stocks such as Abivax SA Sponsored ADR, Viridian Therapeutics, and Fulcrum Therapeutics. ;'>

Currently, the analyst consensus on Perspective Therapeutics is a Strong Buy with an average price target of $13.00, implying a 157.4% upside from current levels. In a report issued on March 6, RBC Capital also maintained a Buy rating on the stock with a price target.

See Insiders’ Hot Stocks on TipRanks >>

Baxter International (BAX)

TD Cowen analyst Josh Jennings reiterated a Hold rating on Baxter International today and set a price target of $22.00. The company’s shares closed last Monday at $17.08.

According to TipRanks.com, Jennings is a 3-star analyst with an average return of 1.2% and a 42.6% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Orchestra BioMed Holdings, and Edwards Lifesciences. ;'>

Currently, the analyst consensus on Baxter International is a Hold with an average price target of $20.27, representing a 18.2% upside. In a report released yesterday, Bank of America Securities also maintained a Hold rating on the stock with a $24.00 price target.

Arvinas Holding Company (ARVN)

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Hold rating on Arvinas Holding Company. The company’s shares closed last Monday at $12.28, close to its 52-week low of $7.53.

According to TipRanks.com, Devarakonda is a 5-star analyst with an average return of 15.1% and a 51.9% success rate. Devarakonda covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals, Protagonist Therapeutics, and Edgewise Therapeutics. ;'>

Arvinas Holding Company has an analyst consensus of Moderate Buy, with a price target consensus of $16.00, a 29.3% upside from current levels. In a report issued on March 3, Bank of America Securities also reiterated a Hold rating on the stock with a $14.00 price target.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).